Glenmede Trust CO Na Revance Therapeutics, Inc. Transaction History

Glenmede Trust CO Na

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $85,023 - $142,293	4,641 Added 41.69%	15,774 $291,000
Q3 2022 Nov 16, 2022	BUY	$14.33 - $28.47 $159,535 - $316,956	11,133 New	11,133 $300,000
Q4 2020 Feb 16, 2021	SELL	$23.41 - $28.34 $45,907 - $55,574	-1,961 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$23.23 - $34.3 $1,417 - $2,092	61 Added 3.21%	1,961 $49,000
Q2 2020 Aug 14, 2020	SELL	$12.6 - $26.55 $18,673 - $39,347	-1,482 Reduced 43.82%	1,900 $46,000
Q4 2019 Feb 12, 2020	SELL	$11.66 - $20.15 $792 - $1,370	-68 Reduced 1.97%	3,382 $54,000
Q2 2019 Aug 13, 2019	BUY	$10.67 - $15.49 $35,637 - $51,736	3,340 Added 3036.36%	3,450 $44,000
Q4 2018 Feb 14, 2019	BUY	$18.06 - $24.96 $1,986 - $2,745	110 New	110 $2,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.